Improving cognitive outcome in cerebral malaria: Insights from clinical and experimental research

Central Nervous System Agents in Medicinal Chemistry

Volumn 11, Issue 4, 2011, Pages 285-295

  de Miranda, Aline Silva ^a   Brant, Fátima ^a   Machado, Fabiana Simão ^a   Rachid, Milene Alvarenga ^a   Teixeira, Antônio Lú ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Adjuvant therapies; Cerebral malaria; Cognitive impairment; Malaria; Neuroprotective interventions; Pharmacological strategies

Indexed keywords

ACETYLCYSTEINE; ANTIMALARIAL AGENT; ARTEMETHER; ARTEMISININ DERIVATIVE; ARTESUNATE; BETA INTERFERON; CHLOROQUINE; DEFEROXAMINE; GLATIRAMER; LMP 420; NIMODIPINE; PANTETHINE; PENTOXIFYLLINE; QUININE DERIVATIVE; RECOMBINANT ALPHA INTERFERON; RECOMBINANT ERYTHROPOIETIN; RO 618048; UNCLASSIFIED DRUG;

BEHAVIOR DISORDER; BRAIN MALARIA; CHILD; COGNITION; COGNITIVE DEFECT; COMA; DRUG MECHANISM; HUMAN; MOTOR DYSFUNCTION; NEUROPROTECTION; NONHUMAN; PATHOGENESIS; PLASMODIUM FALCIPARUM; REVIEW; SEIZURE;

EID: 84855762222     PISSN: 18715249     EISSN: 18756166     Source Type: Journal    
DOI: 10.2174/1871524911106040285     Document Type: Review

References (87)

1. Idro, R.; Jenkins, N.E.; Newton, C.R. Pathogenesis, clinical features, and neurological outcome of cerebral malaria. Lancet Neurol., 2005, 4(12), 827-840.
2. Organization, W.H. Severe falciparum malaria. World Health Organization, Communicable Diseases Cluster. Trans. R Soc Trop. Med. Hyg., 2000, 94 (Suppl 1), 1-90.
3. Snow, R.W.; Guerra, C.A.; Noor, A.M.; Myint, H.Y.; Hay, S.I. The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature, 2005, 434(7030), 214-217.
4. Simmons, M.; Murphy, G.S.; Hayes, C.G. Short report: Antibody responses of mice immunized with a tetravalent dengue recombinant protein subunit vaccine. Am. J. Trop. Med. Hyg., 2001, 65(2), 159-161.
5. Fernando, S.D.; Rodrigo, C.; Rajapakse, S. The 'hidden' burden of malaria: cognitive impairment following infection. Malar. J, 2010, 9, 366.
6. Hunt, N.H.; Golenser, J.; Chan-Ling, T.; Parekh, S.; Rae, C.; Potter, S.; Medana, I.M.; Miu, J.; Ball, H.J. Immunopathogenesis of cerebral malaria. Int. J. Parasitol., 2006, 36(5), 569-582.
7. de Souza, J.B.; Riley, E.M. Cerebral malaria: the contribution of studies in animal models to our understanding of immunopathogenesis. Microbes Infect., 2002, 4(3), 291-300.
8. van der Heyde, H.C.; Nolan, J.; Combes, V.; Gramaglia, I.; Grau, G.E. A unified hypothesis for the genesis of cerebral malaria: sequestration, inflammation and hemostasis leading to microcirculatory dysfunction. Trends Parasitol., 2006, 22(11), 503-508.
9. Miller, L.H.; Baruch, D.I.; Marsh, K.; Doumbo, O.K. The pathogenic basis of malaria. Nature, 2002, 415(6872), 673-679.
10. Springer, A.L.; Smith, L.M.; Mackay, D.Q.; Nelson, S.O.; Smith, J.D. Functional interdependence of the DBLbeta domain and c2 region for binding of the Plasmodium falciparum variant antigen to ICAM-1. Mol. Biochem. Parasitol., 2004, 137(1), 55-64.
11. Clark, I.A.; Cowden, W.B. The pathophysiology of falciparum malaria. Pharmacol. Ther., 2003, 99(2), 221-260.
12. Rogerson, S. J., Carter, R. Severe vivax malaria: newly recognized or rediscovered. PLoS Med., 2008, 5(6), e136.
13. Hunt, N.H.; Grau, G.E. Cytokines: accelerators and brakes in the pathogenesis of cerebral malaria. Trends Immunol., 2003, 24(9), 491-499.
14. Nebl, T., De Veer, M.J., Schofield, L. Stimulation of innate immune responses by malarial glycosylphosphatidylinositol via pattern recognition receptors. Parasitology, 2005, 130 Suppl, S45-62.
15. Jennings, V.M.; Actor, J.K.; Lal, A.A.; Hunter, R.L. Cytokine profile suggesting that murine cerebral malaria is an encephalitis. Infect. Immun., 1997, 65(11), 4883-4887.
16. Medana, I.M.; Hunt, N.H.; Chaudhri, G. Tumor necrosis factoralpha expression in the brain during fatal murine cerebral malaria: evidence for production by microglia and astrocytes. Am. J. Pathol., 1997, 150(4), 1473-1486.
17. Brown, H.; Turner, G.; Rogerson, S.; Tembo, M.; Mwenechanya, J.; Molyneux, M.; Taylor, T. Cytokine expression in the brain in human cerebral malaria. J. Infect. Dis., 1999, 180(5), 1742-1746.
18. Armah, H.; Wired, E.K.; Dodoo, A.K.; Adjei, A.A.; Tettey, Y.; Gyasi, R. Cytokines and adhesion molecules expression in the brain in human cerebral malaria. Int. J. Environ. Res. Public Health, 2005, 2(1), 123-131.
19. Lacerda-Queiroz, N., Rodrigues, D.H., Vilela, M.C., Miranda, A.S., Amaral, D.C., Camargos, E.R, Carvalho, L.J., Howe, C.L, Teixeira, M.M., Teixeira, A.L. Inflammatory changes in the central nervous system are associated with behavioral impairment in Plasmodium berghei (strain ANKA)-infected mice. Exp. Parasitol., 125(3), 271-278.
20. Kossodo, S.; Monso, C.; Juillard, P.; Velu, T.; Goldman, M.; Grau, G.E. Interleukin-10 modulates susceptibility in experimental cerebral malaria. Immunology, 1997, 91(4), 536-540.
21. Sanni, L.A.; Rae, C.; Maitland, A.; Stocker, R.; Hunt, N.H. Is ischemia involved in the pathogenesis of murine cerebral malaria? Am. J. Pathol., 2001, 159(3), 1105-1112.
22. Rae, C.; McQuillan, J.A.; Parekh, S.B.; Bubb, W.A.; Weiser, S.; Balcar, V.J.; Hansen, A.M.; Ball, H.J.; Hunt, N.H. Brain gene expression, metabolism, and bioenergetics: interrelationships in murine models of cerebral and noncerebral malaria. FASEB J, 2004, 18(3), 499-510.
23. Parekh, S.B.; Bubb, W.A.; Hunt, N.H.; Rae, C. Brain metabolic markers reflect susceptibility status in cytokine gene knockout mice with murine cerebral malaria. Int. J. Parasitol., 2006, 36(13), 1409-1418.
24. Wille, U.; Villegas, E.N.; Striepen, B.; Roos, D.S.; Hunter, C.A. Interleukin-10 does not contribute to the pathogenesis of a virulent strain of Toxoplasma gondii. Parasite Immunol., 2001, 23(6), 291-296.
25. Staub, F.; Mackert, B.; Kempski, O.; Peters, J.; Baethmann, A. Swelling and death of neuronal cells by lactic acid. J. Neurol. Sci,. 1993, 119(1), 79-84.
26. Dobbie, M.; Crawley, J.; Waruiru, C.; Marsh, K.; Surtees, R. Cerebrospinal fluid studies in children with cerebral malaria: an excitotoxic mechanism? Am. J. Trop. Med. Hyg, 2000, 62(2), 284-290.
27. Medana, I.M.; Hien, T.T.; Day, N.P.; Phu, N.H.; Mai, N.T.; Chu'ong, L.V.; Chau, T.T.; Taylor, A.; Salahifar, H.; Stocker, R.; Smythe, G.; Turner, G.D.; Farrar, J.; White, N.J.; Hunt, N.H. The clinical significance of cerebrospinal fluid levels of kynurenine pathway metabolites and lactate in severe malaria. J. Infect. Dis., 2002, 185(5), 650-656.
28. Medana, I.M.; Day, N.P.; Salahifar-Sabet, H.; Stocker, R.; Smythe, G.; Bwanaisa, L.; Njobvu, A.; Kayira, K.; Turner, G.D.; Taylor, T.E.; Hunt, N.H. Metabolites of the kynurenine pathway of tryptophan metabolism in the cerebrospinal fluid of Malawian children with malaria. J. Infect. Dis., 2003, 188(6), 844-849.
29. Stone, T.W.; Behan, W.M.; Jones, P.A.; Darlington, L.G.; Smith, R.A. The role of kynurenines in the production of neuronal death, and the neuroprotective effect of purines. J. Alzheimers Dis., 2001, 3(4), 355-366.
30. Sanni, L.A.; Thomas, S.R.; Tattam, B.N.; Moore, D.E.; Chaudhri, G.; Stocker, R.; Hunt, N.H. Dramatic changes in oxidative tryptophan metabolism along the kynurenine pathway in experimental cerebral and noncerebral malaria. Am. J. Pathol., 1998, 152(2), 611-619.
31. Meldrum, B.S. Glutamate as a neurotransmitter in the brain: review of physiology and pathology. J. Nutr., 2000, 130(4S Suppl), 1007S-1015S.
32. Wang, Y.; Qin, Z.H. Molecular and cellular mechanisms of excitotoxic neuronal death. Apoptosis, 2010, 15(11), 1382-1402.
33. Lau, A.; Tymianski, M. Glutamate receptors, neurotoxicity and neurodegeneration. Pflugers Arch., 2010, 460(2), 525-542.
34. Pickering, M.; O'Connor, J.J. Pro-inflammatory cytokines and their effects in the dentate gyrus. Prog. Brain Res., 2007, 163, 339-354.
35. Viviani, B.; Gardoni, F.; Marinovich, M. Cytokines and neuronal ion channels in health and disease. Int. Rev. Neurobiol., 2007, 82, 247-263.
36. Ferguson, A.R.; Christensen, R.N.; Gensel, J.C.; Miller, B.A.; Sun, F.; Beattie, E.C.; Bresnahan, J.C.; Beattie, M.S. Cell death after spinal cord injury is exacerbated by rapid TNF alpha-induced trafficking of GluR2-lacking AMPARs to the plasma membrane. J. Neurosci., 2008, 28(44), 11391-11400.
37. Bezzi, P.; Domercq, M.; Brambilla, L.; Galli, R.; Schols, D.; De Clercq, E.; Vescovi, A.; Bagetta, G.; Kollias, G.; Meldolesi, J.; Volterra, A. CXCR4-activated astrocyte glutamate release via TNFalpha: amplification by microglia triggers neurotoxicity. Nat. Neurosci., 2001, 4(7), 702-710.
38. Leonoudakis, D.; Braithwaite, S.P.; Beattie, M.S.; Beattie, E.C. TNFalpha-induced AMPA-receptor trafficking in CNS neurons; relevance to excitotoxicity? Neuron Glia Biol., 2004, 1(3), 263-273.
39. Stellwagen, D.; Beattie, E.C.; Seo, J.Y.; Malenka, R.C. Differential regulation of AMPA receptor and GABA receptor trafficking by tumor necrosis factor-alpha. J. Neurosci., 2005, 25(12), 3219-3228.
40. Miranda, A.S.; Vieira, L.B.; Lacerda-Queiroz, N.; Souza, A.H.; Rodrigues, D.H.; Vilela, M.C.; Gomez, M.V.; Machado, F.S.; Rachid, M.A.; Teixeira, A.L. Increased levels of glutamate in the central nervous system are associated with behavioral symptoms in experimental malaria. Braz. J. Med. Biol. Res., 2010, 43(12), 1173-1177.
41. Newton, C.R.; Hien, T.T.; White, N. Cerebral malaria. J. Neurol. Neurosurg. Psychiatry, 2000, 69(4), 433-441.
42. Golenser, J.; Waknine, J.H.; Krugliak, M.; Hunt, N.H.; Grau, G.E. Current perspectives on the mechanism of action of artemisinins. Int. J. Parasitol., 2006, 36(14), 1427-1441.
43. Reyburn, H., New WHO guidelines for the treatment of malaria. BMJ, 2010, 340, (c2637) doi: 10.1136/bmj.c2637.
44. Boivin, M.J., Bangirana, P., Byarugaba, J., Opoka, R.O., Idro, R., Jurek, A.M., John, C.C. Cognitive impairment after cerebral malaria in children: a prospective study. Pediatrics, 2007, 119(2), e360-366.
45. John, C.C., Bangirana, P., Byarugaba, J., Opoka, R.O., Idro, R., Jurek, A.M., Wu, B., Boivin, M.J. Cerebral malaria in children is associated with long-term cognitive impairment. Pediatrics, 2008, 122(1), e92-99.
46. Reis, P.A., Comim, C.M., Hermani, F., Silva, B., Barichello, T., Portella, A.C., Gomes, F.C., Sab, I.M., Frutuoso, V.S., Oliveira, M.F., Bozza, P.T., Bozza, F.A., Dal-Pizzol, F., Zimmerman, G.A., Quevedo, J., Castro-Faria-Neto, H.C. Cognitive dysfunction is sustained after rescue therapy in experimental cerebral malaria, and is reduced by additive antioxidant therapy. PLoS Pathog., 2010, 6(6), e1000963.
47. Carter, J.A.; Mung'ala-Odera, V.; Neville, B.G.; Murira, G.; Mturi, N.; Musumba, C.; Newton, C.R. Persistent neurocognitive impairments associated with severe falciparum malaria in Kenyan children. J. Neurol. Neurosurg. Psychiatry, 2005, 76(4), 476-481.
48. Kihara, M.; Carter, J.A.; Newton, C.R. The effect of Plasmodium falciparum on cognition: a systematic review. Trop. Med. Int. Health, 2006, 11(4), 386-397.
49. Murphy, S.C.; Breman, J.G. Gaps in the childhood malaria burden in Africa: cerebral malaria, neurological sequelae, anemia, respiratory distress, hypoglycemia, and complications of pregnancy. Am. J. Trop. Med. Hyg., 2001, 64(1-2 Suppl), 57-67.
50. Mung'Ala-Odera, V.; Snow, R.W.; Newton, C.R. The burden of the neurocognitive impairment associated with Plasmodium falciparum malaria in sub-saharan Africa. Am. J. Trop. Med. Hyg., 2004, 71(2 Suppl), 64-70.
51. Boivin, M.J.Effects of early cerebral malaria on cognitive ability in Senegalese children. J. Dev. Behav. Pediatr., 2002, 23(5), 353-364.
52. Carter, J.A.; Ross, A.J.; Neville, B.G.; Obiero, E.; Katana, K.; Mung'ala-Odera, V.; Lees, J.A.; Newton, C.R. Developmental impairments following severe falciparum malaria in children. Trop. Med. Int. Health, 2005, 10(1), 3-10.
53. Carter, J.A.; Murira, G.M.; Ross, A.J.; Mung'ala-Odera, V.; Newton, C.R. Speech and language sequelae of severe malaria in Kenyan children. Brain Inj., 2003, 17(3), 217-224.
54. Idro, R.; Kakooza-Mwesige, A.; Balyejjussa, S.; Mirembe, G.; Mugasha, C.; Tugumisirize, J.; Byarugaba, J. Severe neurological sequelae and behaviour problems after cerebral malaria in Ugandan children. BMC Res. Notes, 2010, 3, 104.
55. Kihara, M.; Carter, J.A.; Holding, P.A.; Vargha-Khadem, F.; Scott, R.C.; Idro, R.; Fegan, G.W.; de Haan, M.; Neville, B.G.; Newton, C.R. Impaired everyday memory associated with encephalopathy of severe malaria: the role of seizures and hippocampal damage. Malar J, 2009, 8, 273.
56. Mishra, S.K.; Newton, C.R. Diagnosis and management of the neurological complications of falciparum malaria. Nat. Rev.Neurol., 2009, 5(4), 189-198.
57. Martins, Y.C.; Carvalho, L.J.; Daniel-Ribeiro, C.T. Challenges in the determination of early predictors of cerebral malaria: lessons from the human disease and the experimental murine models. Neuroimmunomodulation, 2009, 16(2), 134-145.
58. Sattar, M.A.; Hoque, H.W.; Amin, M.R.; Faiz, M.A.; Rahman, M.R. Neurological findings and outcome in adult cerebral malaria. Bangladesh Med. Res. Counc. Bull, 2009, 35(1), 15-17.
59. Mishra, S.K.; Mohanty, S.; Satpathy, S.K.; Mohapatra, D.N. Cerebral malaria in adults -- a description of 526 cases admitted to Ispat General Hospital in Rourkela, India. Ann. Trop. Med. Parasitol., 2007, 101(3), 187-193.
60. Carter, J.A.; Lees, J.A.; Gona, J.K.; Murira, G.; Rimba, K.; Neville B.G., Newton, C.R. Severe falciparum malaria and acquired childhood language disorder. Dev. Med. Child Neurol., 2006, 48(1), 51-57.
61. Idro, R.; Carter, J.A.; Fegan, G.; Neville, B.G.; Newton, C.R. Risk factors for persisting neurological and cognitive impairments following cerebral malaria. Arch. Dis. Child, 2006, 91(2), 142-148.
62. Lou, J., Lucas, R., Grau, G.E. Pathogenesis of cerebral malaria: recent experimental data and possible applications for humans. Clin. Microbiol. Rev., 2001, 14(4), 810-820, table of contents.
63. Lackner, P.; Beer, R.; Heussler, V.; Goebel, G.; Rudzki, D.; Helbok, R.; Tannich, E.; Schmutzhard, E. Behavioural and histopathological alterations in mice with cerebral malaria. Neuropathol. Appl. Neurobiol., 2006, 32(2), 177-188.
64. Desruisseaux, M.S.; Gulinello, M.; Smith, D.N.; Lee, S.C.; Tsuji, M.; Weiss, L.M.; Spray, D.C.; Tanowitz, H.B. Cognitivedysfunction in mice infected with Plasmodium berghei strain ANKA. J. Infect. Dis., 2008, 197(11), 1621-1627.
65. Dai, M.; Reznik, S.E.; Spray, D.C.; Weiss, L.M.; Tanowitz, H.B.; Gulinello, M.; Desruisseaux, M.S. Persistent cognitive and motor deficits after successful antimalarial treatment in murine cerebral malaria. Microbes Infect., 2010, 12(14-15), 1198-1207.
66. John, C.C.; Panoskaltsis-Mortari, A.; Opoka, R.O.; Park, G.S.; Orchard, P.J.; Jurek, A.M.; Idro, R.; Byarugaba, J.; Boivin, M.J. Cerebrospinal fluid cytokine levels and cognitive impairment in cerebral malaria. Am. J. Trop. Med. Hyg., 2008, 78(2), 198-205.
67. Golenser, J.; McQuillan, J.; Hee, L.; Mitchell, A.J.; Hunt, N.H., Conventional and experimental treatment of cerebral malaria. Int. J. Parasitol., 2006, 36(5), 583-593.
68. van Hensbroek, M.B.; Palmer, A.O.E.; Schneider, G.; Jaffar, S.; Dolan, G.; Memming, H.; Frenkel, J.; Enwere, G.; Bennett, S.; Kwiatkowski, D.; Greenwood, B. The effect of a monoclonal antibody to tumor necrosis factor on survival from childhood cerebral malaria. J. Infect. Dis., 1996, 174(5), 1091-1097.
69. Kremsner, P.G.; Grundmann, H.; Neifer, S.; Sliwa, K.; Sahlmüller, G.; Hegenscheid, B.; Bienzle, U. Pentoxifylline prevents murine cerebral malaria. J. Infect. Dis., 1991, 164(3), 605-608.
70. Di Perri, G.; Di Perri, H.G.; Monteiro, G.B.; Bonora, S.; Hennig, C.; Cassatella, M.; Micciolo, R.; Vento, S.; Dusi, S.; Bassetti, D.; Concia, E. Pentoxifylline as a supportive agent in the treatment of cerebral malaria in children. J. Infect. Dis., 1995, 171(5), 1317-1322.
71. Das, B.K.; Mishra, S.; Padhi, P.K.; Manish, R.; Tripathy, R.; Sahoo, P.K.; Ravindran, B. Pentoxifylline adjunct improves prognosis of human cerebral malaria in adults. Trop. Med. Int. Health, 2003, 8(8), 680-684.
72. Wassmer, S.C.; Cianciolo, G.J.; Combes, V.; Grau, G.E. Inhibition of endothelial activation: a new way to treat cerebral malaria? PLoS Med., 2005, 2(9), e245.
73. Vigario, A.M.; Belnoue, E.; Gruner, A.C.; Mauduit, M.; Kayibanda, M.; Deschemin, J.C.; Marussig, M.; Snounou, G.; Mazier, D.; Gresser, I.; Renia, L. Recombinant human IFN-alpha inhibits cerebral malaria and reduces parasite burden in mice. J. Immunol., 2007, 178(10), 6416-6425.
74. Morrell, C.N.; Srivastava, K.; Swaim, A.; Lee, M.T.; Chen, J.; Nagineni, C.; Hooks, J.J.; Detrick, B. Beta interferon suppresses the development of experimental cerebral malaria. Infect. Immun., 2011, 79(4), 1750-1758.
75. Lackner, P.; Part, A.; Burger, C.; Dietmann, A.; Broessner, G.; Helbok, R.; Reindl, M.; Schmutzhard, E.; Beer, R. Glatiramer acetate reduces the risk for experimental cerebral malaria: a pilot study. Malar. J, 2009, 8, 36.
76. Kaiser, P.; Niederost, B.; Joos, B.; von Wyl, V.; Opravil, M.; Weber, R.; Gunthard, H.F.; Fischer, M. Equal amounts of intracellular and virion-enclosed hepatitis C virus RNA are associated with peripheral-blood mononuclear cells in vivo. J. Infect. Dis., 2006, 194(12), 1713-1723.
77. Picot, S.; Bienvenu, A.L.; Konate, S.; Sissoko, S.; Barry, A.; Diarra, E.; Bamba, K.; Djimde, A.; Doumbo, O.K. Safety of epoietin beta-quinine drug combination in children with cerebral malaria in Mali. Malar. J, 2009, 8, 169.
78. Casals-Pascual, C.; Idro, R.; Gicheru, N.; Gwer, S.; Kitsao, B; Gitau, E.; Mwakesi, R.; Roberts, D.J.; Newton, C.R. High levels of erythropoietin are associated with protection against neurological sequelae in African children with cerebral malaria. Proc. Natl. Acad. Sci. USA, 2008, 105(7), 2634-2639.
79. Kaiser, K.; Texier, A.; Ferrandiz, J.; Buguet, A.; Meiller, A.; Latour, C.; Peyron, F.; Cespuglio, R.; Picot, S. Recombinant human erythropoietin prevents the death of mice during cerebral malaria. J. Infect. Dis., 2006, 193(7), 987-995.
80. Becker, K.; Tilley, L.; Vennerstrom, J.L.; Roberts, D.; Rogerson, S.; Ginsburg, H. Oxidative stress in malaria parasite-infected erythrocytes: host-parasite interactions. Int. J. Parasitol., 2004, 34(2), 163-189.
81. Gordeuk, V.; Thuma, P.; Brittenham, G.; McLaren, C.; Parry, D.; Backenstose, A.; Biemba, G.; Msiska, R.; Holmes, L.; McKinley, E.; Vargas, L.; Gilkeson, R.; Poltera, A.A. Effect of iron chelation therapy on recovery from deep coma in children with cerebral malaria. N. Engl. J. Med., 1992, 327(21), 1473-1477.
82. Thuma, P.E.; Mabeza, G.F.; Biemba, G.; Bhat, G.J.; McLaren, C.E.; Moyo, V.M.; Zulu, S.; Khumalo, H.; Mabeza, P.; M'Hango, A.; Parry, D.; Poltera, A.A.; Brittenham, G.M.; Gordeuk, V.R. Effect of iron chelation therapy on mortality in Zambian children with cerebral malaria. Trans R. Soc. Trop. Med. Hyg., 1998, 92(2), 214-218.
83. Watt, G.; Jongsakul, K.; Ruangvirayuth, R. A pilot study of Nacetylcysteine as adjunctive therapy for severe malaria. QJM, 2002, 95(5), 285-290.
84. Penet, M.F.; Abou-Hamdan, M.; Coltel, N.; Cornille, E.; Grau, G.E.; de Reggi, M.; Gharib, B. Protection against cerebral malaria by the low-molecular-weight thiol pantethine. Proc. Natl. Acad. Sci. USA, 2008, 105(4), 1321-1326.
85. Cabrales, P.; Zanini, G.M.; Meays, D.; Frangos, J.A.; Carvalho, L.J. Murine cerebral malaria is associated with a vasospasm-like microcirculatory dysfunction, and survival upon rescue treatment is markedly increased by nimodipine. Am. J. Pathol., 2010, 176(3), 1306-1315.
86. Clark, C.J.; Mackay, G.M.; Smythe, G.A.; Bustamante, S.; Stone, T.W.; Phillips, R.S. Prolonged survival of a murine model of cerebral malaria by kynurenine pathway inhibition. Infect. Immun., 2005, 73(8), 5249-5251.
87. Miu, J.; Ball, H.J.; Mellor, A.L.; Hunt, N.H. Effect of indoleamine dioxygenase-1 deficiency and kynurenine pathway inhibition on murine cerebral malaria. Int. J. Parasitol., 2009, 39(3), 363-370.